Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA® trial;Kardiovaskuläre Studien-Endpunkte bei Typ-2-Diabetes und die Sulfonylharnstoff-Kontroverse: Rationale für die aktiv kontrollierte CAROLINA®-Studie

Deutsche Medizinische Wochenschrift

Volumn 140, Issue 11, 2015, Pages 831-834

  Gallwitz, Baptist ^a   Thiemann, Sandra ^b   Wörle, Hans Jürgen ^b   Marx, Nikolaus ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

cardiovascular disease; dipeptidyl peptidase 4 inhibitor; oral antidiabetic agents; sulphonylurea; type 2 diabetes

Indexed keywords

SULFONYLUREA; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; SULFONYLUREA DERIVATIVE;

ARTICLE; CARDIOVASCULAR RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; HUMAN;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SULFONYLUREA COMPOUNDS;

EID: 84930226876     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0041-102194     Document Type: Article

References (52)

1. Giugliano D., Standl E., Vilsboll T. et al. Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings? Acta Diabetol: 2009; 46 173 181
2. Ryden L., Grant P. J., Anker S. D. et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J: 2013; 34 3035 3087
3. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Guidance for industry. Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf Letzter Zugriff am 29.04.2015
4. Skyler J. S., Bergenstal R., Bonow R. O. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol: 2009; 53 298 304
5. Nathan D. M., Buse J. B., Davidson M. B. et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia: 2009; 52 17 30
6. Inzucchi S. E., Bergenstal R. M., Buse J. B. et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care: 2012; 35 1364 1379
7. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet: 1998; 352 837 853
8. Holman R. R., Paul S. K., Bethel M. A. et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med: 2008; 359 1577 1589
9. Gerstein H. C., Miller M. E., Byington R. P. et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med: 2008; 358 2545 2559
10. Patel A., MacMahon S., Chalmers J. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med: 2008; 358 2560 2572
11. Duckworth W., Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med: 2009; 360 129 139
12. Moritz T., Duckworth W., Abraira C. Veterans Affairs diabetes trial - corrections. N Engl J Med: 2009; 361 1024 1025
13. Turnbull F. M., Abraira C., Anderson R. J. et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia: 2009; 52 2288 2298
14. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS) VIII. Study design, progress and performance. Diabetologia: 1991; 34 877 890
15. Meinert C. L., Knatterud G. L., Prout T. E. et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes: 1970; 19 01 789 830
16. Seltzer H. S. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes: 1972; 21 976 979
17. Selvin E., Bolen S., Yeh H. C. et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med: 2008; 168 2070 2080
18. Evans J. M., Ogston S. A., Emslie-Smith A. et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia: 2006; 49 930 936
19. Johnson J. A., Majumdar S. R., Simpson S. H. et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care: 2002; 25 2244 2248
20. Rao A. D., Kuhadiya N., Reynolds K. et al. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care: 2008; 31 1672 1678
21. Tzoulaki I., Molokhia M., Curcin V. et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ: 2009; 339 b4731
22. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet: 1998; 352 854 865
23. European Medicines Agency European Medicines Agency 2011 priorities for drug safety research. Anti diabetic drugs: Cardio / cerebrovascular adverse effect and pancreatitis / pancreatic cancer. EMA/425259/2010. http://www.ema.europa.eu/docs/en-GB/document-library/Other/2010/07/WC500094264.pdf Letzter Zugriff am 29.04.2015
24. Ussher J. R., Drucker D. J. Cardiovascular biology of the incretin system. Endocr Rev: 2012; 33 187 215
25. Johansen O. E., Neubacher D., von Eynatten M. et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol: 2012; 11 3
26. Iqbal N., Parker A., Frederich R. et al. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol: 2014; 13 33
27. Williams-Herman D., Engel S. S., Round E. et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord: 2010; 10 7
28. Schweizer A., Dejager S., Foley J. E. et al. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag: 2010; 7 49 57
29. White W. B., Pratley R., Fleck P. et al. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab: 2013; 15 668 673
30. Scirica B. M., Bhatt D. L., Braunwald E. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med: 2013; 369 1317 1326
31. Green J. B., Bethel M. A., Paul S. K. et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J: 2013; 166 983 989
32. Gallwitz B., Rosenstock J., Rauch T. et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet: 2012; 380 475 483
33. Balakumar P., Dhanaraj S. A. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials. Cell Signal: 2013; 25 1799 1803
34. Kröller-Schön S., Knorr M., Hausding M. et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res: 2012; 96 140 149
35. Hocher B., Sharkovska Y., Mark M. et al. The novel DPP-4 inhibitors linagliptin and BI14361 reduce infarct size after myocardial ischemia / reperfusion in rats. Int J Cardiol: 2013; 167 87 93
36. Klamann A., Sarfert P., Launhardt V. et al. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J: 2000; 21 220 229
37. Zeller M., Danchin N., Simon D. et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab: 2010; 95 4993 5002
38. Ye Y., Perez-Polo J. R., Aguilar D. et al. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol: 2011; 106 925 952
39. Krall R. L. Cardiovascular safety of rosiglitazone. Lancet: 2007; 369 1995 1996
40. Kahn S. E., Haffner S. M., Heise M. A. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med: 2006; 355 2427 2443
41. Mazzone T., Meyer P. M., Feinstein S. B. et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA: 2006; 296 2572 2581
42. Nissen S. E., Nicholls S. J., Wolski K. et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA: 2008; 299 1561 1573
43. Gerstein H. C., Ratner R. E., Cannon C. P. et al. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation: 2010; 121 1176 1187
44. Matthews D. R., Dejager S., Ahren B. et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab: 2010; 12 780 789
45. Foley J. E., Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res: 2009; 41 905 909
46. Seck T., Nauck M., Sheng D. et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract: 2010; 64 562 576
47. Chacra A. R., Tan G. H., Ravichandran S. et al. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res: 2011; 8 150 159
48. Garber A., Henry R. R., Ratner R. et al. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab: 2011; 13 348 356
49. Home P. D., Pocock S. J., Beck-Nielsen H. et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet: 2009; 373 2125 2135
50. Frye R. L., August P., Brooks M. M. et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. BARI 2D Study Group. N Engl J Med: 2009; 360 2503 2515
51. Abraira C., Duckworth W. C., Moritz T. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab: 2009; 11 150 156
52. Calles-Escandon J., Lovato L. C., Simons-Morton D. G. et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care: 2010; 33 721 727